SCHEMBL4724167

SCHEMBL4724167

CCCOc1ccccc1-c1[c]nc2ccccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 5/20 0.51
ALDH1A1 P00352 3/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
HTT P42858 1/20 0.43
ATM Q13315 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PDE5A O76074 10/20 0.41
PDE4A P27815 2/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 2/20 0.41
PDE4D Q08499 2/20 0.41
MCHR1 Q99705 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PDE2A O00408 1/20 0.39
PDE6D O43924 1/20 0.39
USP2 O75604 1/20 0.39
PDE9A O76083 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723583 0.93 TLR8 (0.52) TLR8ALDH1A1LMNAMAPTHTT
SCHEMBL4724198 0.89 TLR8 (0.49) TLR8ALDH1A1MAPTHTTPDE5A
SCHEMBL577790 0.81 ALDH1A1 (0.51) TLR8ALDH1A1LMNAMAPTTDP1
SCHEMBL4920374 0.77 TLR8 (0.51) TLR8ALDH1A1LMNAMAPTHTT
SCHEMBL28131881 0.74 PDE5A (0.52) TLR8ALDH1A1LMNAMAPTHTT
SCHEMBL10438816 0.72 HTR7 (0.53) TLR8ALDH1A1LMNAMAPTPDE5A
SCHEMBL4766903 0.71 PDE5A (0.45) TLR8ALDH1A1LMNAMAPTPDE5A
SCHEMBL22033267 0.71 TLR8 (0.56) TLR8ALDH1A1LMNAMAPTPDE5A
SCHEMBL4723778 0.71 PDE5A (0.48) TLR8ALDH1A1LMNAMAPTHTT
SCHEMBL7167304 0.70 TLR8 (0.51) TLR8ALDH1A1LMNAMAPTPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 TLR8 1678/4885ALDH1A1 622/4885LMNA 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.